共 42 条
- [1] Paules C., Subbarao K., Influenza, Lancet, 390, pp. 697-708, (2017)
- [2] Han A.X., De Jong S.P.J., Russell C.A., Co-evolution of immunity and seasonal influenza viruses, Nat. Rev. Microbiol, 21, pp. 805-817, (2023)
- [3] Kandeil A., Patton C., Jones J.C., Jeevan T., Harrington W.N., Trifkovic S., Seiler J.P., Fabrizio T., Woodard K., Turner J.C., Et al., Rapid evolution of A(H5N1) influenza viruses after intercontinental spread to North America, Nat. Commun, 14, (2023)
- [4] Hayden F.G., Asher J., Cowling B.J., Hurt A.C., Ikematsu H., Kuhlbusch K., Lemenuel-Diot A., Du Z., Meyers L.A., A Piedra P., Et al., Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment, Clin. Infect. Dis, 74, pp. 532-540, (2022)
- [5] Yin H., Jiang N., Shi W., Chi X., Liu S., Chen J.-L., Wang S., Development and Effects of Influenza Antiviral Drugs, Molecules, 26, (2021)
- [6] Gu R.-X., Liu L.A., Wei D.-Q., Structural and energetic analysis of drug inhibition of the influenza A M2 proton channel, Trends Pharmacol. Sci, 34, pp. 571-580, (2013)
- [7] Park E.K., Castrucci M.R., Portner A., Kawaoka Y., The M2 Ectodomain Is Important for Its Incorporation into Influenza A Virions, J. Virol, 72, pp. 2449-2455, (1998)
- [8] Schepens B., De Vlieger D., Saelens X., Vaccine options for influenza: Thinking small, Curr. Opin. Immunol, 53, pp. 22-29, (2018)
- [9] Matthys A., Saelens X., Promises and challenges of single-domain antibodies to control influenza, Antivir. Res, 222, (2024)
- [10] Yu C., Ding W., Zhu L., Zhou Y., Dong Y., Li L., Liu J., Wang Y., Li Z., Zhu L., Et al., Screening and characterization of inhibitory vNAR targeting nanodisc-assembled influenza M2 proteins, iScience, 26, (2023)